Orexigen Therapeutics (OREX) Price Target Raised to $26 at Piper
Get Alerts OREX Hot Sheet
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 9 | New: 42
Join SI Premium – FREE
(Updated - March 3, 2015 12:46 PM EST)
Piper Jaffray analyst Charles Duncan maintained an Overweight rating on Orexigen Therapeutics (NASDAQ: OREX) and raised his price target to $26.00 (from $16.00) intra-day Tuesday, after the company released an 8-K regarding U.S. patent 8,969,371 ('371) and a series of applications.
Duncan notes that disclosed in the patent and applications are details on the LIGHT study interim at 25% of events. He notes Contrave demonstrated a statistically significant benefit over placebo for CV events, including CV death. Additionally, the patent extends patent protection for Contrave to 2034.
Duncan said the news could turn the obesity/metabolic syndrome market on its head. "We see this CVOT effect as surprisingly positive and it has several implications, in our view for the potential of Contrave," he commented. "These include possibly driving competitive advantage in the US market, and enhancing probability of approvals ex-US. We also see the new patent as “galvanizing” the IP protection behind Contrave and thus ensuring that it is a longlived asset. Finally, in terms of life cycle management efforts in combining the drug in a regimen with anti-diabetic drugs, we see these data as ramping interest in these efforts by the company and its potential collaborators."
The analyst also sees newsflow soon. He said the 50% interim analysis is expected sometime this quarter, based on prior comments from the company.
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $5.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades DFI Retail Group Holdings (DFI:SP) (DFILF) to Hold, 'expect H&B to progress more slowly'
- GCL Technology Holdings (3800:HK) (GCPEF) PT Raised to HK$1.90 at HSBC
- Neogrid Participacoes SA (NGRD3:BZ) PT Lowered to BRL1.20 at Citi, 'combination of stale top-line growth and heavier expenses will keep margins pressured'
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot Comments, Momentum Movers, Trader TalkRelated Entities
Piper Jaffray, Charles DuncanSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!